March 1, 2017
Bristol-Myers Squibb Company plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. GRAIL aims to develop highly sensitive blood tests that detect cancer in its early stages by combining the power of high intensity cancer DNA sequencing, large clinical studies, and leading edge computer science into a diagnostic platform.
As an investor, Bristol-Myers Squibb will gain early access to the comprehensive clinical trial databases of GRAIL that may serve as a rich resource for understanding tumor genomics. Moreover, Bristol-Myers Squibb and GRAIL have agreed to form a research collaboration that would enable Bristol-Myers Squibb to examine its clinical data using GRAIL’s analytic tools to inform research and development decisions, guide strategies to advance point of care companion diagnostics and potentially improve selection, care and management of patients through more targeted treatments.
Francis Cuss, MB BChir, FRCP, chief scientific officer, Bristol-Myers Squibb, said: “A key enabler of our Immuno-Oncology strategy is to leverage precision medicine to speed the selection of the most effective combinations of therapies for patients. GRAIL’s future innovation potential is significant. Liquid biopsies hold the potential to support much earlier intervention and better define individual patient characteristics that may enhance treatment decisions.”